Tolazamide is no longer marketed in the United Staes. Because no information is available on the use of tolazamide during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Monitor breastfed infants for signs of hypoglycemia such as jitteriness, excessive sleepiness, poor feeding, seizures cyanosis, apnea, or hypothermia. If there is concern, monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with hypoglycemic agents.[1,2]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Everett JA. Use of oral antidiabetic agents during breastfeeding. J Hum Lact 1997;13:319-21. [PubMed: 9429368]
2.
Berlin CM, Briggs GG. Drugs and chemicals in human milk. Semin Fetal Neonatal Med 2005;10:149-59. [PubMed: 15701580]
Substance Identification
Substance Name
Tolazamide
CAS Registry Number
1156-19-0
Drug Class
Breast Feeding
Lactation
Milk, Human
Hypoglycemic Agents
Sulfonylurea Compounds
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
